LIXIANA® (edoxaban): an oral, once-daily, direct factor Xa inhibitor

Nonvalvular atrial fibrillation (NVAF)

  • Prevention of stroke and systemic embolism in eligible adult patients with nonvalvular atrial fibrillation

Venous thromboembolism (VTE)

  • Treatment of deep vein thrombosis (DVT)*

  • Treatment of pulmonary embolism (PE)*

  • Prevention of recurrent DVT and PE following initial treatment for DVT and/or PE

Dossing Icon

Convenient Once-Daily Dosing

Convenient dosing with no mealtime requirements addresses lifestyle factor concerns of your NVAF and VTE patients.1


Proven Safety

Superior reduction in the primary safety endpoints vs warfarin for NVAF and VTE.2,3



Efficay Icon

Proven Efficacy

Address clinical concerns in NVAF and VTE patients with efficacy comparable to well-managed warfarin.1-3



Patient Consultation Icon

Helpful Resources

Download tools and resources that can help you and your patients get the latest news and events.



Indications and Summary of Product Characteristics

Indications and Summary of Product Characteristics

LIXIANA® (edoxaban) is approved for patients with NVAF and VTE.

Contraindications and Drug Interactions

Convenient
Once-Daily Dosing1

Convenient
Once-Daily Dosing

Convenient dosing with no mealtime requirements addresses lifestyle factor concerns of your NVAF and VTE patients.1

Proven Safety2,3

Proven Safety

Superior reduction in the primary safety endpoints vs warfarin for NVAF and VTE.2,3

The Lixiana® Difference

The LIXIANA® Difference

Once-daily LIXIANA® (edoxaban) addresses both clinical concerns...
AND lifestyle factors.

Proven Efficacy1-3

Proven Efficacy

Address clinical concerns in NVAF and VTE patients with efficacy comparable to well-managed warfarin.1-3

Helpful Resources

Helpful Resources

Download tools and resources that can help you and your patients get the latest news and events.

  • *

    Following initial use of parenteral anticoagulant for at least 5 days.3

  • §

    Major bleeding in nonsurgical patients was defined as4

    1. Fatal bleeding, and/or
    2. Symptomatic bleeding in critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome, and/or
    3. Bleeding causing a fall in haemoglobin level of 20 g/L-1 (1.24 mml/L-1) or more, or leading to transfusing of 2 or more units of whole blood or red cells.
  • Clinically relevant bleeding is defined as the composite of major and clinically relevant nonmajor bleeding. Clinically relevant nonmajor bleeding was defined as overt bleeding not meeting the criteria for major bleeding§ but associated with medical intervention, unscheduled contact (visit or telephone call) with a physician, (temporary) cessation of study treatment, or associated with any other discomfort such as pain, or impairment of activities of daily life.3

  • Such as cyclosporine, dronedarone, ketoconazole, erythromycin.